Absolute Quantification of Allergens from Complex Mixtures: A New Sensitive Tool for Standardization of Allergen Extracts for Specific Immunotherapy

2011 ◽  
Vol 10 (4) ◽  
pp. 2113-2122 ◽  
Author(s):  
Ulla Seppälä ◽  
Claire Dauly ◽  
Sarah Robinson ◽  
Martin Hornshaw ◽  
Jørgen Nedergaard Larsen ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Absolute Quantification ◽  
Complex Mixtures ◽  
Sensitive Tool ◽  
Allergen Extracts

Absolute Quantification of Specific Proteins in Complex Mixtures Using Visible Isotope-Coded Affinity Tags

2004 ◽  
Vol 76 (14) ◽  
pp. 4104-4111 ◽  
Author(s):  
Yu Lu ◽  
Patricia Bottari ◽  
Frantisek Turecek ◽  
Ruedi Aebersold ◽  
Michael H. Gelb
Keyword(s):  
Absolute Quantification ◽  
Complex Mixtures ◽  
Affinity Tags ◽  
Specific Proteins

Perspectives in Allergen-Specific Immunotherapy: Molecular Evolution of Peptide- and Protein-Based Strategies

2020 ◽  
Vol 21 (2) ◽  
pp. 203-223 ◽  
Author(s):  
Alain Jacquet
Keyword(s):  
Specific Immunotherapy ◽  
Patient Adherence ◽  
Recombinant Allergen ◽  
Preclinical Studies ◽  
Allergen Specific Immunotherapy ◽  
Adverse Side Effects ◽  
Long Duration ◽  
Tremendous Progress ◽  
Allergen Extracts

Allergen-specific Immunotherapy (AIT), through repetitive subcutaneous or sublingual administrations of allergen extracts, represents up to now the unique treatment against allergic sensitizations. However, the clinical efficacy of AIT can be largely dependent on the quality of natural allergen extracts. Moreover, the long duration and adverse side effects associated with AIT negatively impact patient adherence. Tremendous progress in the field of molecular allergology has made possible the design of safer, shorter and more effective new immunotherapeutic approaches based on purified and characterized natural or recombinant allergen derivatives and peptides. This review will summarize the characteristics of these different innovative vaccines including their effects in preclinical studies and clinical trials.

Comparison of Six Different Allergen Extracts for Subcutaneous Specific Immunotherapy in Children: An Open-Labelled, Prospective, Controlled Observational Trial

2019 ◽  
Vol 180 (4) ◽  
pp. 284-290
Author(s):  
Matthias Volkmar Kopp ◽  
Inke R. König ◽  
Frank Friedrichs ◽  
Hans Ulrich Umpfenbach ◽  
Bodo Niggemann ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Observational Trial ◽  
Allergen Extracts ◽  
Subcutaneous Specific Immunotherapy

Allergy testing: the role of recombinant allergens

2006 ◽  
Vol 44 (2) ◽  
Author(s):  
Nadine Mothes ◽  
Rudolf Valenta ◽  
Susanne Spitzauer
Keyword(s):  
Specific Immunotherapy ◽  
Simultaneous Detection ◽  
In Vitro Tests ◽  
Recombinant Allergen ◽  
Recombinant Allergens ◽  
Type I ◽  
Type I Allergy ◽  
Specific Igg ◽  
Allergen Extracts

AbstractCurrently, diagnosis of type I allergy is performed using crude allergen extracts, which allow the identification of the allergen-containing source responsible for type I allergic symptoms (e.g., allergic rhino-conjunctivitis, asthma) but not the disease-eliciting molecules. With the introduction of recombinant allergens produced by molecular biology techniques, a large panel of allergenic molecules has become available. The application of these recombinant allergens for in vitro tests has led to new forms of component-resolved diagnosis (CRD) and allows the establishment of a patient's individual reactivity profile. The increasing number of recombinant allergens characterized during the last decade has allowed the development of chip-based allergy tests for simultaneous detection of up to 5000 different allergens and epitopes. The introduction of these recombinant allergen-based tests into clinical practice improves the selection of patients for traditional specific immunotherapy and allows monitoring of the immunological efficacy of specific immunotherapy by measuring allergen-specific IgG antibodies. Besides their diagnostic application, recombinant allergens and hypoallergenic derivatives thereof have also been used as vaccines in clinical trials, and recent results have shown their usefulness for the treatment of type I allergy.

scholarly journals Allergy vaccines for specific immunotherapy

2021 ◽  
Vol 98 (1) ◽  
pp. 104-112
Author(s):  
S. Yu. Petrova ◽  
S. V. Khlgatian ◽  
V. M. Berzhets ◽  
A. V. Vasileva
Keyword(s):  
Clinical Trials ◽  
Specific Immunotherapy ◽  
High Efficiency ◽  
Cell Epitope ◽  
Allergic Diseases ◽  
The Body ◽  
Allergen Specific Immunotherapy ◽  
Allergenic Activity ◽  
Immunological Effects ◽  
Allergen Extracts

Allergen-specific immunotherapy (ASIT) has been used for more than a hundred years to treat patients with IgEmediated allergic diseases. The most common allergens have been obtained using molecular cloning technology in the past two decades. To increase the safety of immunotherapy, a large group of genetically modified allergens with reduced allergenic activity was created. The mechanism of action of these therapeutic allergens differs from natural allergen extracts, and more research is needed to understand how desensitization occurs in each case. The objective of this review is to introduce readers to new therapeutic allergy vaccines and their structural modification features as well as immunological effects on the body. To achieve this objective, we have analyzed and systematized the experimental developments presented in the literature on the main directions of creating new allergy vaccines: hypoallergenic derivatives of recombinant allergens, T cell epitope-based allergy vaccines and B cell epitope-based allergy vaccines, DNA vaccines.Summing up the results of the research presented in the literature, it is necessary to note the high heterogeneity of designs used to achieve the high efficiency of the developed therapeutic allergens. All allergy vaccines presented in the review solve the tasks set by the researchers: in experimental animal models they induce immunogenicity or tolerance, in clinical trials they reduce the symptoms of allergic reactions. The the effectiveness of the proposed medicinal products is quite high but its evaluation requires further long-term preclinical and clinical trials to confirm the safety and harmlessness of the created allergy vaccines.

Sign in / Sign up

Export Citation Format

Share Document